Citations

Clear

4207 citation(s) found for "Chen, Yu".

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
Armstrong, Andrew J., Morris, M., Abida, Wassim , Aggarwal, Rahul R., Antonarakis, Emmanuel S., Attard, Gerhardt , Beltran, Himisha, Bryce, Alan H. , Carducci, Michael A. , Cheng, Heather H., Dahut, William L. , Emmett, Louise , Fizazi, Karim, Gafita, Andrei, George, Daniel J., Hermann, Ken, Hofman, Michael S., Hope, MD Thomas A., Hussain, Maha, Kelly, W. Kevin, Kuo, Phillip H. , Liu, Glenn X., Morgans, Alicia K., McKay, Rana R., Nanus, David, Nelson, P., Reichert, Zachery R. , Ryan, Charles J. , Sartor, A. Oliver, Schwartz, Lawrence H., Sharifi, Nima , Stadler, Walter M., Stein, M., Sternberg, Cora N., Szmulewitz, Russell Z., Tagawa, Scott T., Sokolova, Alexandra O., Wyatt, Alex, Yu, Evan Y., Halabi, S., Scher, Howard I., Group, for the PCWG4 Writing, Alumkal, Joshi J. , Aparicio, Ana, Barata, Pedro C., Drake, Charles G., Hamid, Anis , Heath, Elisabeth I. , Nauseef, Jones, Lage, Daniel E. , Mallak, Nadine , Patnaik, Akash, Prepelica, Kristofer, Rowe, Steven P., Slovin, Susan F. , Taplin, Mary‐Ellen , Zorko, Nicholas, Carducci, Michael A. , Halabi, Susan , Cheng, Heather H. , Antonarakis, Emmanuel S. , Morris, Michael J. , Armstrong, Andrew J. , Nauseef, Jones T. , Antonarakis, Emmanuel S. , Zorko, Nicholas A. , Armstrong, Andrew J , Morris, Michael J , Aggarwal, Rahul , Antonarakis, Emmanuel S , Beltran, Himisha , Bryce, Alan H , Cheng, Heather H , Chen, Delphine L , Chi, Kim N , Childs, Daniel S , Dahut, William , Emmett, Louise , Fizazi, Karim , Gafita, Andrei , George, Daniel J , Hermann, Ken , Hofman, Michael S , Hope, Thomas A , Hussain, Maha H A , Kelly, W Kevin , Kessler, Elizabeth , Lang, Joshua M , Liu, Glenn , Marshall, Catherine H , Morgans, Alicia K , McKay, Rana R , Nelson, Peter S , Paller, Channing J , Reichert, Zachery R , Sartor, A Oliver , Schöder, Heiko , Sharifi, Nima , Stadler, Walter M , Stein, Mark , Sternberg, Cora N , Szmulewitz, Russell Z , Tagawa, Scott T , Sokolova, Alexandra O , Wyatt, Alexander , Yamoah, Kosj , Yu, Evan Y , Halabi, Susan , Antonarakis, Emmanuel S , Zorko, Nicholas A , Nauseef, Jones T , N., Kim , Childs, Daniel S. , Fizazi, Karim , Gafita, Andrei , George, Daniel J. , Hofman, Michael S. , Lang, Joshua M. , Liu, Glenn , Marshall, Catherine H. , Morgans, Alicia K. , McKay, Rana R. , Paller, Channing J. , Sartor, Oliver , Schöder, Heiko , Schwartz, Lawrence H., Stadler, Walter M. , Tagawa, Scott T. , Scher, Howard I. , Aparicio, Ana, Barata, Pedro C. , Drake, Charles G. , Graff, Julie Nicole , Patnaik, Akash , Rathkopf, Dana E , Rettig, Matthew B.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2026 | Volume: 44 | Issue: 13 | Pages: 1249-1265

10.1200/jco-25-02834 | PMID 41744290 Get It

PURPOSE The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer. Methods We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced prostate cancer. RESULTS PCWG4 redefines terminology around the disease state and previous therapies in a patient-centric context and terminology focused on androgen pathway modulation. We consider imaging, with a particular focus on positron emission tomography (PET)–defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, response and delay/prevent end points, intervals for reassessments including imaging, and patient-reported outcome determination. We provide recommendations in a biomarker-based context of use for the intended indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework. CONCLUSION PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator–naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.
Methods for improved bileaflet aortic valve detection prior to transcatheter aortic valve replacement
Tretter, Justin T. , Eleid, Mackram F., Bedogni, Francesco, Rodés-Cabau, Josep, Regueiro, Ander, Testa, Luca, Ellenbogen, Kenneth A., Leon, M B, Ben-Haim, Shlomo, Eleid, Mackram F. , Bedogni, Francesco , Rodés‐Cabau, Josep , Regueiro, Ander , Testa, Luca , Chen, Shmuel , Galhardo, Attílio , Ellenbogen, Kenneth A , Leon, Martin B.

Mayo Clinic

Frontiers in Cardiovascular Medicine | February 23, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1755835 | PMID 41808748 Get It

Background Bileaflet aortic valve prevalence in transcatheter aortic valve replacement (TAVR) patients is poorly defined. We evaluated a TAVR cohort to determine the bileaflet aortic valve prevalence and understand features which may improve detection. In addition, we related valvar morphology to the occurrence of permanent pacemaker implantation (PPI) following TAVR. Methods Aortic valvar morphology diagnosis was recorded from the pre-procedural cardiac CTA reports prior to TAVR. Commissural angles, comparison of commissural heights, and dynamic visual inspection of the aortic valve were subsequently evaluated on pre-procedural cardiac CTA by an expert cardiac anatomist and imager, methods previously validated in a surgical cohort, to determine aortic valvar morphology and compared to the historical diagnosis. Relationships between valvar morphological characteristics with the need for PPM within 30-days post-TAVR were determined. Results Four-hundred and thirty-three (mean age 81.3 ± 6.6 years, 53.8% female) underwent TAVR [corrected diagnosis: 393 (90.8%) trileaflet vs. 40 (9.2%) bileaflet valves]. Bileaflet valves were historically misdiagnosed in 80% of pre-procedural cardiac CTA reports. Thirty-four (85.0%) had intercoronary leaflet fusion [mean commissural angle = 148.1 (18.3) degrees]. A commissural angle threshold of 141.1 degrees had a sensitivity of 0.73 and specificity of 0.86 for identifying a bileaflet valve. PPI post-TAVR occurred in 38% bileaflet vs. 19% trileaflet patients ( p = 0.0114 ) [unadjusted OR for bileaflet valve requiring PPI = 2.54, 95% CI (1.25–5.01)]. Conclusions Bileaflet aortic valves are commonly misdiagnosed. Assessment of the commissural angle and comparison of commissural heights may improve CTA-based diagnostic accuracy prior to TAVR. Improved detection may guide improved outcomes in this higher risk population.
Contemporary Perspectives on J‐Wave Syndromes: An Expert Consensus Statement
Nademanee, K., Wilde, Arthur A.M. , Ackerman, Michael J., Behr, Elijah R, Chen, P S, Chung, Fa Po, Coronel, R F M, Haissaguerre, Michel, Jiang, Chenyang, Khongphatthanayothin, Apichai , Makita, N., Morita, Hiroshi, Nakagawa, Hiroshi , Ngarmukos, Tachapong , Nogami, Akihiko, PAPPONE, CARLO, Priori, Silvia G., Rosso, Raphaël , Shimizu, W, Veerakul, Gumpanart, Makita, Naomasa , Behr, Elijah R. , Coronel, Ruben , Nademanee, Koonlawee , Nademanee, Koonlawee , Wilde, Arthur A M , Behr, Elijah Raphael , Chung, Fa Po , Coronel, Ruben , Makita, Naomasa , Morita, Hiroshi , Nakagawa, Hiroshi , Ngarmukos, Tachapong , Nogami, Akihiko , Shimizu, Wataru , Ackerman, Michael J. , Bezzina, Connie R. , Haissaguerre, Michel , Jiang, Chenyang , Juang, Jyh‐Ming Jimmy , Pappone, Carlo , Priori, Silvia G. , Viskin, Sami

Mayo Clinic

Journal of Arrhythmia | February 21, 2026 | Volume: 42 | Issue: 1 | Pages: No page available

10.1002/joa3.70284 | PMID 41738055 Get It

ABSTRACT J‐wave syndromes (JWS)—comprising Brugada syndrome (BrS) and early repolarization syndrome (ERS)—are important causes of malignant ventricular arrhythmias and sudden cardiac death in patients whose hearts appear structurally normal. Since the 2016 consensus, advances in genetics, pathophysiology, and therapy have redefined both understanding and management. BrS, once viewed as a purely electrical disorder, is now recognized along a microstructural–electrical continuum, with sodium‐channel dysfunction and subtle epicardial fibrosis of the right ventricular outflow tract as key contributors. Likewise, ERS—historically considered benign—carries significant risk when inferolateral J‐waves coexist with arrhythmic events. Genetically, SCN5A remains the sole gene with definitive disease association, while polygenic susceptibility materially modulates risk, underscoring complex inheritance. Risk stratification remains challenging: patients with prior cardiac arrest or arrhythmic syncope are highest risk, whereas asymptomatic individuals warrant multiparametric assessment integrating clinical features, ECG markers, electrophysiologic studies, and genetics. For decades, treatment centered on implantable cardioverter‐defibrillators and quinidine, both limited by availability, tolerance, and device complications. More recently, epicardial substrate ablation has emerged as a transformative therapy, with large registries and randomized trials demonstrating durable suppression of ventricular fibrillation and acceptable safety. This APHRS‐organized international consensus updates and extends the 2016 Expert Consensus and the 2022 ESC Guidelines, providing contemporary diagnostic frameworks, pragmatic risk‐stratification tools, and treatment algorithms for BrS and ERS. It emphasizes JWS as a microstructural–electrical disease spectrum and elevates substrate ablation as a major therapeutic advance, while outlining priorities for genetics, risk‐stratification and treatment algorithms.
A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling
Zanetti, Giorgia , Chen, A. C., Fathi, Farshid, Suek, Nathan , Teteloshvili, Nato , Li, Hao Wei , Ding, Xiaolan , Traum, Daniel , Kaestner, Klaus, Hoang, Ryan E., Bremer, Edwin , Parent, Audrey V. , Sykes, Megan, Maharlooei, Mohsen Khosravi, Khosravi-Maharlooei, Mohsen , Legut, Mateusz , Fathi, Farshid , Kaestner, Klaus H. , Sewell, Andrew Kelvin , Creusot, Rémi J.

Mayo Clinic

No container title available | February 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.19.706929 | PMID 41756994 Get It

Abstract Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, which impairs efficacy and poses risks of off-target autoreactivity. Here we present a CRISPR-based platform that completely and selectively eliminates both endogenous TCR-α and -β chains without affecting introduced transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, markedly enhancing the expression, pairing fidelity, and functional potency of transgenic receptors. Using a clinically relevant HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and significantly enhances tumor clearance in vivo in human immune system (HIS) mice, while preventing graft-versus-host disease (GVHD). Targeted locus amplification revealed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, confirming genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that removal of endogenous receptors increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of stem cell–derived islet grafts (SC-islets) in vivo . This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a strong preclinical rationale for dual endogenous TCR removal as a route to improved specificity, safety, and therapeutic efficacy in TCR-based cell therapies.
Abstract PS3-07-23: Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole
Chapman, J. W., Bayani, Jane , SenGupta, S., Bartlett, J. M. S., Piper, T., Quintayo, M. A., Virk, Shakeel , Goss, P. E., Ingle, J. N., Ellis, M. J., Sledge, G. W., Budd, G. T., Ansari, R. H., Tozer, Richard , D'Souza, D. P., Chalchal, H., Spadafora, S., Stearns, V., Perez, E. A., Gelmon, K. A., Whelan, T. J., Elliott, C., Shepherd, L. E., Chen, B. E., Taylor, K. J., Whelan, Timothy J. , Bartlett, J. M. S., Quintayo, Mary Anne , Ingle, J. N., Budd, G.T., Rabaglio, Manuela , D’Souza, David , Chalchal, H., Stearns, Vered , Shepherd, Lois E. , Chen, B. E., Taylor, K. J., Whelan, Timothy J

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-07-23-PS3-07-23

10.1158/1557-3265.sabcs25-ps3-07-23 Get It

Abstract Background: Survivor plots permit adjustment by baseline demographics and clinical characteristics; log-normal survival analysis may be more robust than a Cox model under departures from model assumptions. We depicted distant disease-free survival (DDFS) for statistically standardized quantitated ER, PgR, and HER2. Methods: We utilized CCTG MA.27 (NCT00066573), an adjuvant phase III trial of exemestane versus anastrozole in postmenopausal women with ER+ and/or PgR+ tumours. IHC ER, PgR, and HER2 HSCORE were centrally assessed by machine image quantitation, and statistically standardized to mean of 0, standard deviation (SD) of 1 following Box-Cox variance stabilization transformations of square for ER, natural logarithm (ln) and square root for PgR, and ln for HER2. For the ln transformation, 0.1 was added to 0 HSCOREs for a stable transformation. The primary endpoint was DDFS at the longest trial follow-up of 4.1 years. For log-normal survival analysis, ln(time) is a linear function of covariates and had a normal distribution; the Cox models were log-linear for covariates. Survival was depicted with log-normal and Cox survivor plots adjusted at the means of age, T and N stage, grade, lymphovascular invasion, treatment, and baseline patient demographics. We examined ER and PgR ASCO/CAP cut-points at (0; >0), HER2 cut-points at (IHC 0, 0 stain; IHC 0, (0,10%] stain; IHC 1+; IHC 2+; IHC 3+), and ER/PgR/HER2 standardized cut-points at standard deviations about mean of 0 (<-1; (-1,0]; (0,1]; >1). P was based on the likelihood ratio criterion (∼Χ2 (1)) for the addition of ER/PgR/HER2 to the model of baseline covariates, and had nominal significance if P<0.05. Log-normal and Cox multivariable regressions with unstandardized and standardized categorical, and continuous, ER, PgR, and HER2 were adjusted by baseline covariates; 2-sided Wald tests had nominal significance if P<0.05. Results: Of 7576 MA.27 patients, 2325 patients had quantitated image analysis assessments for ER, PgR, and HER2; 113 of 2325 (4.9%) patients experienced a DDFS event during follow-up. Multivariable log-normal survival analysis indicated DDFS was significantly longer for patients with T1 (p=0.01), N0 (p=.002), and grade 1/2 tumors (p=0.01); similar significance levels were found with a Cox model. Log-normal survivor plots were smooth, while Cox survivor plots were step-wise discontinuous at events. Adjusted log-normal survivor plots indicated similar 5-year DDFS for patients by standardized ER categories (p=0.43): 95.4% for those with ER <-1.0 (n=401); 95.8%, for (-1.0,0.0] (n=737); 96.1%, for (0.0,1.0] (n=737); and 96.4%, for >1.0 (n=450). The log-normal standardized PgR survivor plots indicated patients had significantly different 5-year DDFS (p<.001) by categories, with both ln and square root transformations of HSCORE: with a ln transformation, 93.7% for <-1.0 (n=607); 95.4%, for (-1.0,0.0] (n=390); 96.8%, for (0.0,1.0] (n=826); and 97.8%, for >1.0 (n=502). Patients had similar 5-year DDFS by standardized HER2 categories (p=0.71): 96.2% for <-1.0 (n=83); 96.0%, for (-1.0,0.0] (n=1201); 95.9%, for (0.0,1.0] (n=527); and 95.7%, for >1.0 (n=514). In full fit multivariable log-normal survival analyses, DDFS was not significantly different for ER (p=0.51-0.89) and HER2 (p=0.12-0.98); higher PgR was associated with significantly better DDFS (p=0.01 to <.001). Adjusted Cox survival analyses had similar results. Conclusions: Survivor plots adjusted for baseline demographic and clinical characteristics provided similar indications of significance for standardized ER, PgR, and HER2 as those seen in multivariable models with both log-normal and Cox survival analyses. Higher PgR was associated with significantly better DDFS. Citation Format: J. W. Chapman, J. Bayani, S. SenGupta, J. M. S. Bartlett, T. Piper, M. A. Quintayo, S. Virk, P. E. Goss, J. N. Ingle, M. J. Ellis, G. W. Sledge, G. T. Budd, M. Rabaglio, R. H. Ansari, R. Tozer, D. P. D'Souza, H. Chalchal, S. Spadafora, V. Stearns, E. A. Perez, K. A. Gelmon, T. J. Whelan, C. Elliott, L. E. Shepherd, B. E. Chen, K. J. Taylor. Survivor plots for quantitated adjunctive statistically standardized ER, PgR, and HER2 in adjuvant postmenopausal breast cancer: Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-07-23.
Abstract PS3-07-10: Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot
Giridhar, K. V., Goetz, M. P., Yau, C., Wallace, A. M., Boughey, J., Arora, M., Stringer-Reasor, E., Nangia, C., Gallagher, C., Elias, A., Trivedi, M. S., Omene, Coral , Veer, L. van 't, Swigart, L. Brown, Hirst, G. L., Symmans, W. F., Borowsky, A. D., Hylton, N., Vakalvas, C., Wei, M., Reid, J. M., Alhafaji, S., Chen, N., Mukhtar, R. M., Huppert, L., Opopade, O., Esserman, L. J., Chein, Aung, Giridhar, K. V., Goetz, M. P., Yau, C., Wallace, A.M., Falkson, Carla I. , Boughey, J. C., Stringer-Reasor, Erica , Nangia, C., Elias, A., Zimmer, Alexandra S. , Trivedi, M. S., Veer, L. J. van 't, Swigart, Lamorna Brown , Hirst, G. L., Symmans, W. Fraser , Borowsky, A. D., Onishi, Natsuko , Hylton, N. M., Wei, M., Reid, J. M., Alkhafaji, Silver , Chen, N., Mukhtar, R., Huppert, L. A., Esserman, L. J.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-07-10-PS3-07-10

10.1158/1557-3265.sabcs25-ps3-07-10 Get It

Abstract Background: (Z)-endoxifen (ENDX) is an oral SERM that dually targets ERα (> 5 ng/ml) and PKCβ1 (>500 ng/ml). It has been tested in the endocrine resistant setting at doses of 20-360 mg/day; however, the optimal dose in an endocrine naïve population is not defined. We explored 10 mg/day dose of neoadjuvant ENDX in the Endocrine Optimization Pilot (EOP) of I-SPY2. Methods: EOP eligibility included pts with Stage II/III HR+ HER2- breast cancer, MammaPrint (MP) low. Pts with MP High1 scores were eligible if clinically node-negative. Pts received ENDX 10 mg orally once daily for 6 cycles (each cycle = 28 days). Premenopausal pts started ovarian function suppression on cycle 2, day 1. ENDX was continued until the day prior to surgery. The primary study endpoint was feasibility, defined as >75% of pts completing >75% of ENDX. Baseline (T0), 3-wk (T1) biopsies, and the surgical specimen (T3) were assessed centrally for Ki-67. Rates of modified preoperative endocrine prognostic index (mPEPI) 0 were reported, defined as pT1-2 pN0, Ki67< 2.7%, or pathologic complete response. A genomic index for sensitivity to endocrine therapy (SET) index was done at T0. Breast MRI measurement of functional tumor volume (FTV) was performed at T0, T1, 12 weeks (T2), and pre-operatively (T3). Blood was collected for tumor informed ctDNA at T0, T1, T2, T3 and for pharmacokinetic (PK) steady state concentrations (Css) at T1. Safety data using CTCAE V5 is reported. Results: Between March 2023 and May 2024, 20 pts were enrolled in this arm. The median age was 52.5 years (range 32 -73), 13 (65%) were premenopausal, and 55% had clinically positive lymph nodes. Tumors were MPHigh1 in 3 pts (15%) and SET2,3 index high in 16 pts (80%). The primary endpoint was met with 95% of study participants completing ≥75% of therapy. The T0 median Ki-67 was 10.5% (range 2-60%). At T1 (n=19) and T3 (n=18), median Ki-67 was 5% (range 0-35%) and 5% (range 0-45%), respectively. The 3-week rate of Ki-67 ≤10% at T1 was 61.5% in premenopausal and 71.4% in postmenopausal women. The rate of Ki-67 ≤10% at surgery was 81.8% in premenopausal and 57.1% in postmenopausal women. An mPEPI score of 0 was observed in 1 (5%) of participants. The median T0 FTV was 8.9 ccs (range 0.9 to 251.1). The median T3 FTV was 1.3 ccs (range 0 to 11.2) and the median change in FTV from T0 to T3 was -72.0% (range -88.5% to -61.6%). ctDNA analysis was performed in 17 pts longitudinally across 64 blood samples.10 pts had positive ctDNA at T0, with 7 converting to ctDNA undetectable during treatment with ENDX. 1/7 pts who was ctDNA negative at T0 became positive at T1 and then reverted to undetectable ctDNA. The other 6 pts remained ctDNA negative at all timepoints. The median ENDX T1 Css was 79.3 ng/mL (range 73.6 - 906.4 ng /mL). The most common side effects reported were Grade 1 hot flush (70%), nausea (40%), fatigue (40%), and insomnia (35%). Grade 2 side effects included fatigue (15%) and night sweats (5%). No dose reductions or discontinuations due to toxicity occurred. Conclusions: ENDX at 10 mg was well tolerated and demonstrated reductions in Ki-67, MRI FTV, and ctDNA. The ISPY2 EOP is currently enrolling patients to ENDX 40 mg/day (intended to dually target ERα and PKCβ1) in combination with abemaciclib (with and without OFS). Citation Format: K. V. Giridhar, M. P. Goetz, C. Yau, A. M. Wallace, C. Falkson, J. Boughey, M. Arora, E. Stringer-Reasor, C. Nangia, C. Gallagher, A. Elias, A. Zimmer, M. S. Trivedi, C. Omene, L. van 't Veer, L. Brown Swigart, G. L. Hirst, W. Symmans, A. D. Borowsky, N. Onishi, N. Hylton, C. Vakalvas, M. Wei, J. M. Reid, S. Alhafaji, N. Chen, R. M. Mukhtar, L. Huppert, O. Opopade, L. J. Esserman, A. Chein. Low dose (Z)-endoxifen in the I-SPY2 Endocrine Optimization Pilot [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-07-10.
Abstract PS2-08-14: Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer
Deshmukh, S. Kumar, Wu, S., Xiu, Joanne , Sledge, G. W., Trapani, D., Leone, J., Chumsri, S., Lustberg, M. B., Hong, C., Yao, S., Ernstoff, M., Paulos, C. M., Lesinski, G. B., Madabhushi, A., Badve, S., Kalinsky, K., Kalinski, P., Gandhi, Shipra , Trapani, Dario , Leone, J. P. , Chumsri, S., Lustberg, Maryam , Hong, Chi‐Chen , Takabe, Kazuaki , Opyrchal, Mateusz , Chalasani, Pavani , Paulos, Chrystal M. , Lesinski, Gregory B , Badve, Sunil , Kalinsky, K. M.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-08-14-PS2-08-14

10.1158/1557-3265.sabcs25-ps2-08-14 Get It

Abstract Background: Triple-negative breast cancer (TNBC) is an aggressive yet immunogenic subtype of breast cancer (BC) and the only one with FDA-approved immune checkpoint inhibitor (ICI) - pembrolizumab. Currently, PD-L1 (22C3) is the companion biomarker for predicting pembrolizumab benefit, but its utility is limited by spatial/temporal heterogeneity, assay variability, and modest correlation with treatment response. Chemokines such as CXCL9, CXCL10, and CCL5 recruit CD8+ T cells into the tumor microenvironment and have been associated with improved response to ICI, but their predictive value alongside PD-L1 remains unclear. Here, we examined the relationship between these chemokines, PD-L1, and pembrolizumab efficacy in TNBC. Methods: We analyzed 3662 TNBC tumors profiled by NGS (592, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences). Immune cells were estimated using WTS deconvolution (Quantiseq). PD-L1 positivity was defined as >10% CPS (PharmDx 22C3). CXCL9/CXCL10/CCL5-high (H) and -low (L) TNBC were classified by RNA expression above or below 50th percentile. Real-world median overall survival (mOS) was derived from insurance claims and calculated from start of pembrolizumab to last contact using Kaplan-Meier. Statistical significance was assessed by chi-square and Mann-Whitney U with multiple comparison adjustments (q<0.05). Results: TNBC expressed higher levels of CXCL9, CXCL10, and CCL5 (N = 3662, median TPM: 5.3, 14.8, and 15.1) compared to HER2+ (N = 1344; 4.8, 10.1, 10.6) and HR+HER2- BC (N = 6097; 2.7, 6.6, 9.4), all q<0.05. Moderate correlations were observed between PD-L1 CPS and each chemokine (r = 0.41, p<.01). PD-L1-positive tumors had better mOS (24.3 months (m) vs 18.6 m, HR 0.75, 95% CI 0.6-0.92, p=0.007) compared to PD-L1-negative TNBC post-pembrolizumab. Among PD-L1-negative tumors, those with CXCL9-H had better mOS (26.9 m vs 15.8 m for CXCL9-L, HR 0.61, 95% CI 0.45-0.82, p=0.001) post-pembrolizumab. Among PD-L1-positive tumors, CXCL10-H and CCL5-H was associated with improved mOS (CXCL10-H: 25.7 m vs. 20.7 m for CXC10-L, p = 0.03; CCL5-H: 26.7 vs. 18.5 m for CCL5-L, p = 0.03) post-pembrolizumab. PD-L1 negative CXCL9-H, PD-L1 positive CXCL10-H and PD-L1 positive CCL5-H groups showed higher infiltration of CD8+ T cell, B cells, M1/M2 macrophages, Tregs. They also exhibited higher T cell inflamed score, IFNy score and MAPK activation score vs. CXCL9-L, CXCL10-L and CCL5-L groups (Table). Conclusions: In TNBC, a chemokine signature comprising CXCL9, CXCL10 and CCL5 refines PD-L1 based prediction of pembrolizumab benefit. Specifically, high CXCL10 or CCL5 expression in PD-L1-positive tumors, and high CXCL9 expression in PD-L1-negative tumors, were associated with improved survival post pembrolizumab and immune-rich microenvironment. These findings support the use of chemokine profiling to complement PD-L1 and enhance patient selection for ICI therapy in TNBC. Citation Format: S. Gandhi, S. Deshmukh, S. Wu, J. Xiu, G. Sledge Jr., D. Trapani, J. Leone, S. Chumsri, M. Lustberg, C. Hong, S. Yao, K. Takabe, M. Ernstoff, M. Opyrchal, P. Chalasani, C. Paulos, G. Lesinski, A. Madabhushi, S. Badve, K. Kalinsky, P. Kalinski. Chemokine signatures improve PD-L1-based prediction of pembrolizumab response in triple-negative breast cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-08-14.
Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins
Zhang, Chengyue , He, Yixuan, Zhang, Jingzhou, Feldman, William B. , Ding, Yi , Pasaniuc, Bogdan, Chang, Diana, Chen, Qingwen , Lasky-Su, Jessica, Hecker, Julian, Tobin, Martin D., Chen, Jing , Kalra, S. , Pratte, Katherine A., Im, Hae Kyung, Wan, Emily S., Manichaikul, Ani, Silverman, Edwin K., Bowler, Russell P., Lange, Leslie A., Ortega, Victor E., Cho, Michael H., Moll, Matthew R., Konigsberg, Iain R. , Zhang, Jingzhou , Chikowore, Tinashe , Hu, Xiaowei , Paşaniuc, Bogdan , Lasky‐Su, Jessica , Tobin, Martin D. , Pratte, Katherine , Wan, Emily S. , Manichaikul, Ani , Silverman, Edwin K. , Bowler, Russell P. , Lange, Leslie A., Ortega, Victor E. , Martin, Alicia R. , Cho, Michael H. , Moll, Matt

Mayo Clinic

JCI Insight | February 19, 2026 | Volume: 11 | Issue: 7 | Pages: No page available

10.1172/jci.insight.199951 | PMID 41712304 Get It

BACKGROUND We constructed multi-trait polygenic risk scores (PRSs) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validated their performance in diverse cohorts, and identified PRS-related proteins for potential therapeutic targeting. METHODS PRSmix + , a multi-trait PRS framework, is used to train a composite PRS (PRS multi ) in COPDGene non-Hispanic White participants ( n = 6,647). Associations of PRS multi with COPD status (GOLD 2–4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American ( n = 2,466), ECLIPSE ( n = 1,858), Mass General Brigham Biobank ( n = 15,152), and All of Us ( n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRS multi and were validated with proteomic data in COPDGene ( n = 5,173) and UK Biobank ( n = 5,012). RESULTS PRSmix + selected 7 traits for PRS multi . In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects [RE] OR 1.58 [95% CI: 1.28–1.94]) and exacerbation frequency (meta-analysis RE β 0.21 [95% CI: 0.11–0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRSs that were also validated with measured protein levels in COPDGene and UK Biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include RAGE/sRAGE, IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. CONCLUSIONS Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. TRIAL REGISTRATION COPDGene: ClinicalTrials.gov NCT00608764; ECLIPSE: ClinicalTrials.gov NCT00292552.
Abstract B032: Characterization of αPD1, αPD-L1, αCTLA4, and αLAG3 as mono and combination therapy in live tumor fragments using an ex vivo cytokine profiling platform
Adstamongkonkul, Pichet , Kulkarni, Tanmay, Nasreen, Amreen , Marhefke, Nathan, Chen, Nina, Ramasubramanian, T S., Hrycyniak, Laura , Zweng, Julie, Euw, Erika von , Vivelo, Christina A. , Mukhopadhyay, D., Ramos, Hilario J. , Cunin, Pierre , Bhattacharya, Santanu , Ramasubramanian, T. S., Caenepeel, Sean , Mukhopadhyay, Debabrata , Gierman, Hinco J.

Mayo Clinic

Cancer Immunology Research | February 19, 2026 | Volume: 14 | Issue: 2_Supplement | Pages: B032-B032

10.1158/2326-6074.io2026-b032 Get It

Abstract Background While immune checkpoint inhibitors (ICIs) provide durable clinical benefit in a subset of patients, current biomarkers to predict response lack accuracy. Ex vivo cytokine profiling has shown promise for improved accuracy but has been mostly limited to ICIs targeting PD-1 [Voabil et al, 2021]. This poses the question of whether ICIs beyond αPD-1 – such as CTLA4 blockade, which has been reported to act within the draining lymph node – would be amenable to similar approaches. The Elephas platform characterizes response to ICIs in live tumor fragments (LTFs) from core needle biopsies (CNBs) and resections using longitudinal cytokine profiling. Using a panel of 7 clinically relevant ICI regimens, we demonstrate cytokine responses across diverse tumor types, characterize similarities and differences in cytokine response profiles across different ICIs, and explore specimen variability in responses across ICI treatments. Methods CNBs were collected through 3 observational clinical trials (NCT05478538, NCT05520099, NCT0634962) and a biobank collection study, while resections were procured from NCI CHTN. LTFs were generated using an automated cutting device and encapsulated in hydrogel. LTFs were treated with mono (αPD-1, αPD-L1, αCTLA4, αLAG-3) or combination therapy (αPD-1/αCTLA4, αPD-1/αLAG-3, αPD-L1/αCTLA4) using a sequential treatment strategy in which isotype control followed by ICI were added to the same tissue in a single well. This approach enabled the comparison of control and treatment conditions while mitigating the effects of tumor heterogeneity. Production rates for 46 cytokines were measured using a multiplex assay. Remaining T-cell reactivity was also evaluated at the end of the assay to better understand the presence of functional T cells in LTFs. Results Unsupervised hierarchical clustering of cytokine profiling data from CNB LTFs across 129 patients identified defined responder and non-responder clusters. Within the response cluster, 4 subclusters with distinct immune phenotypes were identified. While tight clustering of samples treated with the same ICI was not observed, some enrichment of samples treated with combination ICIs was observed within individual subclusters. Further, cytokine responses to αCTLA4 monotherapy were observed, suggesting that CTLA4 blockade may act beyond the draining lymph node. LTFs from resections enabled the characterization of cytokine response profiles across treatment conditions within individual specimens, including the magnitude of cytokine response and variability in cytokine response profiles. Evaluation of T-cell reactivity provided further insight into the presence of functional T-cells in LTFs and the extent of T-cell activation achieved by ICI treatment. Conclusions This study demonstrates the platform’s ability to recapitulate diverse mechanisms of immune activation ex vivo, enabling the characterization of cytokine responses to clinically relevant ICI mono or combination therapy in live tumor tissue and supporting future efforts to improve ICI response prediction beyond αPD-1. Citation Format: Pichet Adstamongkonkul, Pierre Cunin, Santanu Bhattacharya, Tanmay Kulkarni, Amreen Nasreen, Nathan Marhefke, Nina Chen, T S. Ramasubramanian, Laura Hrycyniak, Julie Zweng, Erika von Euw, Christina Vivelo, Sean Caenepeel, Debabrata Mukhopadhyay, Hinco Gierman, Hilario Ramos. Characterization of αPD1, αPD-L1, αCTLA4, and αLAG3 as mono and combination therapy in live tumor fragments using an ex vivo cytokine profiling platform [abstract]. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B032.